H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 279 500 KRW -0.36% Market Closed
Market Cap: 3.5T KRW
Have any thoughts about
Hugel Inc?
Write Note

Hugel Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hugel Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
H
Hugel Inc
KOSDAQ:145020
Operating Income
â‚©156.5B
CAGR 3-Years
14%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Operating Income
â‚©314B
CAGR 3-Years
-24%
CAGR 5-Years
0%
CAGR 10-Years
8%
SK Bioscience Co Ltd
KRX:302440
Operating Income
-â‚©12B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Operating Income
â‚©33.8B
CAGR 3-Years
-20%
CAGR 5-Years
-9%
CAGR 10-Years
-9%
P
PharmaResearch Co Ltd
KOSDAQ:214450
Operating Income
â‚©109.6B
CAGR 3-Years
30%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Operating Income
-â‚©5.7B
CAGR 3-Years
39%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

Hugel Inc
Glance View

Market Cap
3.5T KRW
Industry
Biotechnology

In the bustling landscape of the global biopharmaceutical market, Hugel Inc. stands out as a formidable player rooted in the dynamic world of aesthetics and medical treatments. Established in South Korea, Hugel Inc. embarked on its journey with a focus on producing botulinum toxin products, a niche that has rapidly expanded due to a surge in demand for non-surgical cosmetic procedures. The company navigated early challenges with innovative prowess, crafting a strong reputation for high-quality products that cater to a global clientele. The ethos of innovation and safety permeates its operations, enabling Hugel to diversify its portfolio and steadily gain traction in international markets, including significant footprints in Asia, Europe, and Latin America. Through a network of strategic partnerships and a robust distribution channel, Hugel not only pioneered advancements in cosmetic treatments but also cemented its status as a key contributor to the evolving aesthetics industry. The company's revenue model hinges upon the development, production, and distribution of its botulinum toxin and hyaluronic acid-based products. By focusing on research and development, Hugel enhances its capacity to innovate, delivering cutting-edge solutions that meet the rising demands of beauty-conscious consumers. Its business strategy also extends to therapeutics, exploring potential applications of its core products to address various medical conditions. Hugel's financial growth is propelled by the continuous expansion into new geographical territories and the gradual introduction of new, clinically-researched products. As the company continues to navigate the intricate regulatory landscapes of the pharmaceutical industry, it maintains an unwavering commitment to quality, ensuring that each product meets rigorous safety standards while catering to the evolving desires of its diverse customer base worldwide.

Intrinsic Value
251 724.56 KRW
Overvaluation 10%
Intrinsic Value
Price
H

See Also

What is Hugel Inc's Operating Income?
Operating Income
156.5B KRW

Based on the financial report for Sep 30, 2024, Hugel Inc's Operating Income amounts to 156.5B KRW.

What is Hugel Inc's Operating Income growth rate?
Operating Income CAGR 5Y
19%

Over the last year, the Operating Income growth was 40%. The average annual Operating Income growth rates for Hugel Inc have been 14% over the past three years , 19% over the past five years .

Back to Top